(Q43035320)

12 November 2017

A short course of pegylated interferon-alpha in acute HCV hepatitis (English)

1 reference

12 November 2017

G Calleri

1

1 reference

12 November 2017

G Cariti

2

1 reference

12 November 2017

F Gaiottino

3

1 reference

12 November 2017

F G De Rosa

4

1 reference

12 November 2017

O Bargiacchi

5

1 reference

12 November 2017

S Audagnotto

6

1 reference

12 November 2017

S Quaglia

7

1 reference

12 November 2017

T De Blasi

8

1 reference

12 November 2017

P Romano

9

1 reference

12 November 2017

A Traverso

10

1 reference

12 November 2017

G Leo

11

1 reference

12 November 2017

R Carbone

12

1 reference

12 November 2017

B Del Mastro

13

1 reference

12 November 2017

M Tinelli

14

1 reference

12 November 2017

P Caramello

15

1 reference

12 November 2017

G Di Perri

16

1 reference

12 November 2017

1 February 2007

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

14

1 reference

12 November 2017

116-121

1 reference

12 November 2017

2

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Natural course of acute hepatitis C: a long-term prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

When and how to treat acute hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00802.X

10.1111/J.1365-2893.2006.00802.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference